

S2 Table. Univariate Cox-regression analysis for overall survival of each variable in each cohort

Variable	Cohort A (n=4,063)		Cohort B (n=2,721)	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (yr)	1.012 (1.008-1.016)	< 0.001	1.010 (1.005-1.015)	< 0.001
Female sex	0.895 (0.813-0.985)	0.023	0.751 (0.647-0.871)	< 0.001
Body mass index (kg/m ²)	0.966 (0.953-0.979)	< 0.001	0.941 (0.923-0.958)	< 0.001
Hypertension	0.962 (0.882-1.049)	0.383	1.078 (0.960-1.210)	0.202
Diabetes mellitus	1.032 (0.939-1.133)	0.513	1.097 (0.967-1.244)	0.151
Viral etiology	0.856 (0.781-0.938)	0.001	0.777 (0.688-0.876)	< 0.001
Hepatitis B	0.852 (0.785-0.926)	< 0.001	0.799 (0.715-0.893)	< 0.001
Hepatitis C	1.088 (0.962-1.231)	0.179	0.995 (0.840-1.179)	0.952
Hepatitis B+C	0.984 (0.705-1.374)	0.924	1.483 (0.954-2.308)	0.080
Heavy alcohol intake	1.226 (1.126-1.335)	< 0.001	1.287 (1.147-1.444)	< 0.001
Ascites				
Controlled	2.671 (2.415-2.955)	< 0.001	3.104 (2.718-3.544)	< 0.001
Uncontrolled	3.302 (2.891-3.772)	< 0.001	4.286 (3.619-5.076)	< 0.001
Hepatic encephalopathy				
Mild	2.014 (1.571-2.582)	< 0.001	1.848 (1.294-2.640)	0.001
Severe	2.347 (1.298-4.244)	< 0.005	2.077 (0.988-4.366)	0.054
Multiple tumors	2.224 (2.053-2.409)	< 0.001	2.326 (2.084-2.595)	< 0.001
Above triple tumors	3.031 (2.782-3.303)	< 0.001	3.380 (3.015-3.789)	< 0.001
Maximum tumor diameter (cm)				
> 3	2.944 (2.701-3.209)	< 0.001	3.680 (3.247-4.171)	< 0.001
> 5	3.688 (3.401-4.000)	< 0.001	4.740 (4.238-5.302)	< 0.001
> 10	4.134 (3.779-4.523)	< 0.001	5.178 (4.596-5.835)	< 0.001
Portal vein invasion	4.742 (4.347-5.173)	< 0.001	5.152 (4.585-5.788)	< 0.001
Regional LN metastasis	4.217 (3.686-4.825)	< 0.001	4.404 (3.699-5.243)	< 0.001
Distant metastasis	4.903 (4.351-5.525)	< 0.001	6.340 (5.461-7.360)	< 0.001
Platelet ($\times 10^9/L$)	1.002 (1.002-1.002)	< 0.001	1.003 (1.003-1.004)	< 0.001
ALT (IU/L)	1.000 (1.000-1.001)	< 0.001	1.001 (1.001-1.002)	< 0.001
Albumin (g/L)	0.541 (0.513-0.572)	< 0.001	0.459 (0.423-0.497)	< 0.001
Total bilirubin (IU/L)	1.054 (1.044-1.064)	< 0.001	1.080 (1.063-1.097)	< 0.001
Serum creatinine (IU/L)	1.036 (0.992-1.083)	0.110	1.079 (1.020-1.141)	0.008
Prothrombin time, INR	1.968 (1.712-2.261)	< 0.001	1.302 (1.185-1.431)	< 0.001
α -Fetoprotein (ng/mL)	1.000 (1.000-1.000)	< 0.001	1.000 (1.000-1.000)	0.001
Child-Pugh class				
B (7-9)	2.534 (2.321-2.767)	< 0.001	2.930 (2.603-3.298)	< 0.001
C (10-15)	3.725 (3.126-4.439)	< 0.001	3.847 (3.006-4.923)	< 0.001
MELD	1.073 (1.064-1.083)	< 0.001	1.052 (1.043-1.061)	< 0.001
BCLC stage				
Stage A	2.058 (1.634-2.593)	< 0.001	2.873 (2.029-4.068)	< 0.001
Stage B	4.469 (3.493-5.719)	< 0.001	6.433 (4.477-9.241)	< 0.001
Stage C	8.933 (7.114-11.217)	< 0.001	12.413 (8.828-17.455)	< 0.001
Stage D	12.591 (9.671-16.394)	< 0.001	16.150 (10.939-23.843)	< 0.001

HR, hazard ratio; CI, confidence interval; LN, lymph node; ALT, alanine aminotransferase; INR, international normalized ratio; MELD, model for end-stage liver disease; BCLC, Barcelona-clinic liver cancer.